ERBB2 and neoplasm: In addition, three patients (20.0%) with HER2-positive primary tumours were treated with anti-HER2 therapy (alone or combined with chemotherapy), and five patients (33.3%) received cyclin inhibitor therapy combined with hormone therapy.